Tirzepatide in Dubai
Dual GLP-1/GIP receptor agonist. SURMOUNT trial data, Mounjaro vs research-grade comparison, titration protocols, and next-generation alternatives available in the UAE.
Tirzepatide is a dual GLP-1/GIP receptor agonist that achieved 22.5% mean body weight reduction in SURMOUNT trials—surpassing semaglutide’s 15%. Marketed as Mounjaro (diabetes) and Zepbound (weight management), it remains limited in Dubai pharmacies. Research-grade tirzepatide is available for laboratory use, though researchers studying the obesity pipeline are increasingly focused on retatrutide (24.2% weight loss), which adds a third glucagon receptor for superior metabolic efficacy.
Retatrutide pen 30mg (triple agonist, 24.2% weight loss data). 99.262% HPLC purity. 2-hour Dubai delivery.
What Is Tirzepatide?
Tirzepatide is a dual GLP-1/GIP (glucose-dependent insulinotropic polypeptide) receptor agonist developed by Eli Lilly. Often called a “twincretin,” it simultaneously activates two incretin receptors that regulate appetite, insulin secretion, and energy metabolism. This dual mechanism produces greater weight loss than single-agonist GLP-1 compounds like semaglutide.
Tirzepatide is marketed under two brand names: Mounjaro (approved for type 2 diabetes) and Zepbound (approved for chronic weight management). Both contain the same tirzepatide molecule at once-weekly subcutaneous injection doses ranging from 2.5mg to 15mg. For injection protocols, see our Mounjaro/tirzepatide injection guide.
SURMOUNT Trial Weight Loss Data
The SURMOUNT clinical trial program established tirzepatide as the most effective approved weight loss compound:
- SURMOUNT-1: 15mg weekly → 22.5% mean body weight reduction over 72 weeks (vs 2.4% placebo) in adults with obesity without diabetes
- SURMOUNT-2: In patients with type 2 diabetes and obesity → 14.7% weight loss at 15mg over 72 weeks
- SURMOUNT-3: Combined with intensive lifestyle intervention → 26.6% weight loss at the highest dose
- SURMOUNT-4: Withdrawal study confirming weight regain upon discontinuation—participants who continued treatment maintained weight loss while those switching to placebo regained approximately two-thirds of lost weight
These results exceeded semaglutide’s STEP trial benchmarks by a significant margin, establishing the value of multi-receptor agonism in obesity research. However, triple-agonist retatrutide has since demonstrated even greater efficacy (24.2%) by adding the glucagon receptor. For a full pipeline comparison, see our best obesity drug 2026 analysis.
Tirzepatide Availability in Dubai
Branded Products: Mounjaro & Zepbound
Branded tirzepatide availability in Dubai is limited. Mounjaro has been approved in the UAE but pharmacy stock remains inconsistent. Zepbound (the weight-management indication) has not yet achieved widespread distribution in the region. Wait times of 2–8 weeks are common for clinic prescriptions.
Research-Grade Tirzepatide
Research-grade tirzepatide is available in Dubai for in-vitro laboratory use. Unlike branded products, supply is not dependent on pharmaceutical distribution channels. Key advantages include HPLC purity verification, published COA documentation, and consistent availability without waitlists.
Clinic Pricing vs Research-Grade
Dubai clinics prescribing Mounjaro for weight management charge AED 2,000–5,000+ per month, including consultation and monitoring fees. Insurance coverage is inconsistent, with many providers excluding weight-management prescriptions. Research-grade tirzepatide for laboratory use is available at a fraction of this cost. Contact Remy Peptides via WhatsApp for current pricing.
Tirzepatide vs Semaglutide vs Retatrutide
Each generation of incretin-based compounds adds receptor targets and improves efficacy:
| Compound | Receptors | Weight Loss | Status |
|---|---|---|---|
| Semaglutide | GLP-1 only (1) | ~15% | Approved (Ozempic/Wegovy) |
| Tirzepatide | GLP-1 + GIP (2) | ~22.5% | Approved (Mounjaro/Zepbound) |
| Retatrutide | GLP-1 + GIP + glucagon (3) | 24.2% | Phase 3 (TRIUMPH) |
The key differentiator is the glucagon receptor: retatrutide’s third target increases energy expenditure and hepatic lipid oxidation—metabolic effects that neither semaglutide nor tirzepatide produce. For researchers studying multi-agonist mechanisms, retatrutide represents the current frontier. See our retatrutide vs semaglutide comparison for detailed data.
Tirzepatide Dosing & Titration
Published Titration Schedule (SURMOUNT Trials)
The published tirzepatide titration protocol escalates over 20 weeks to the maximum dose:
- Weeks 1–4: 2.5 mg/week (starting dose)
- Weeks 5–8: 5 mg/week
- Weeks 9–12: 7.5 mg/week
- Weeks 13–16: 10 mg/week
- Weeks 17–20: 12.5 mg/week
- Week 21+: 15 mg/week (maintenance)
Each dose is maintained for four weeks before escalation to minimise gastrointestinal side effects (nausea, diarrhoea). Dose adjustments may be made based on tolerability. For research protocol planning, use our protocol calculator.
Delivery Across the UAE
- Dubai: 2-hour delivery — all areas
- Abu Dhabi: Next-day delivery
- Sharjah & other emirates: Next-day delivery
All shipments use temperature-controlled packaging. Contact us via WhatsApp at +34 672 737 521 for ordering and availability.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and published clinical trial data. Read our editorial policy →
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216.
- Garvey WT, et al. Tirzepatide in Patients with Type 2 Diabetes and Obesity (SURMOUNT-2). Lancet. 2023;402(10402):613-626.
- Jastreboff AM, et al. Retatrutide Phase 2 Trial. N Engl J Med. 2023;389(6):514-526.
Retatrutide Pen 30 mg
Next-generation triple agonist. 24.2% weight loss data. 99.262% HPLC purity. 2-hour Dubai delivery.
Order Retatrutide Pen →